Publications

Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R et al..  2016.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.. Contemp Clin Trials. 50:166-77.

Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R et al..  2016.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.. Contemp Clin Trials. 50:166-77.

Kaunzner UW, Kumar G, Askin G, Gauthier SA, Nealon N, Vartanian T, Perumal J.  2016.  A study of patients with aggressive multiple sclerosis at disease onset.. Neuropsychiatr Dis Treat. 12:1907-12.

Kaunzner UW, Kumar G, Askin G, Gauthier SA, Nealon N, Vartanian T, Perumal J.  2016.  A study of patients with aggressive multiple sclerosis at disease onset.. Neuropsychiatr Dis Treat. 12:1907-12.

Kaunzner UW, Salamon E, Pentsova E, Rosenblum M, Karimi S, Nealon N, Lavi E, Jamieson DG.  2017.  An Acute Disseminated Encephalomyelitis-Like Illness in the Elderly: Neuroimaging and Neuropathology Findings.. J Neuroimaging. 27(3):306-311.

Kaunzner UW, Salamon E, Pentsova E, Rosenblum M, Karimi S, Nealon N, Lavi E, Jamieson DG.  2017.  An Acute Disseminated Encephalomyelitis-Like Illness in the Elderly: Neuroimaging and Neuropathology Findings.. J Neuroimaging. 27(3):306-311.

Wang Y, Spincemaille P, Liu Z, Dimov A, Deh K, Li J, Zhang Y, Yao Y, Gillen KM, Wilman AH et al..  2017.  Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.. J Magn Reson Imaging. 46(4):951-971.

Wang Y, Spincemaille P, Liu Z, Dimov A, Deh K, Li J, Zhang Y, Yao Y, Gillen KM, Wilman AH et al..  2017.  Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.. J Magn Reson Imaging. 46(4):951-971.

Wang Y, Spincemaille P, Liu Z, Dimov A, Deh K, Li J, Zhang Y, Yao Y, Gillen KM, Wilman AH et al..  2017.  Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.. J Magn Reson Imaging. 46(4):951-971.

Wang Y, Spincemaille P, Liu Z, Dimov A, Deh K, Li J, Zhang Y, Yao Y, Gillen KM, Wilman AH et al..  2017.  Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.. J Magn Reson Imaging. 46(4):951-971.

Kappos L, Havrdova E, Giovannoni G, Khatri BO, Gauthier SA, Greenberg SJ, You X, Wang P, Giannattasio G.  2017.  No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.. Mult Scler. 23(13):1736-1747.

Kappos L, Havrdova E, Giovannoni G, Khatri BO, Gauthier SA, Greenberg SJ, You X, Wang P, Giannattasio G.  2017.  No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.. Mult Scler. 23(13):1736-1747.

Kaunzner UW, Kang Y, Monohan E, Kothari PJ, Nealon N, Perumal J, Vartanian T, Kuceyeski A, Vallabhajosula S, P Mozley D et al..  2017.  Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.. Mult Scler Relat Disord. 15:27-33.

Kaunzner UW, Kang Y, Monohan E, Kothari PJ, Nealon N, Perumal J, Vartanian T, Kuceyeski A, Vallabhajosula S, P Mozley D et al..  2017.  Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.. Mult Scler Relat Disord. 15:27-33.

Kaunzner UW, Kang Y, Monohan E, Kothari PJ, Nealon N, Perumal J, Vartanian T, Kuceyeski A, Vallabhajosula S, P Mozley D et al..  2017.  Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.. Mult Scler Relat Disord. 15:27-33.

Kaunzner UW, Kang Y, Monohan E, Kothari PJ, Nealon N, Perumal J, Vartanian T, Kuceyeski A, Vallabhajosula S, P Mozley D et al..  2017.  Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.. Mult Scler Relat Disord. 15:27-33.